ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

In-house Hepatitis B Vaccine

Its studies are mostly in Hepatitis B, led by PT Bio Farma.

Furthest: phase 3, since Sep 28, 20261 company-led study, 1 open or runningNext primary completion: Feb 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
PT Bio Farma11 open or runningphase 3since Sep 28, 2026Sep 28, 2026Feb 2027phase 3 · NCT07854847

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 28, 2026First study: phase 3 study in Hepatitis BFirst studyNCT07854847 · 270 planned

Ahead

  1. Feb 2027Primary completion: phase 3 study in Hepatitis BNCT07854847

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“In-house Hepatitis B Vaccine”name, by rule

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07854847Hepatitis B3Not yet recruitingFeb 2027270

How it is read

Names in the registry

  • “In-house Hepatitis B Vaccine”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.